Save up -80% on Gliclazide
Note: this is a drug discount program, not an insurance plan.
2018 Price of Gliclazide
Apo-Gliclazide Mr 30 mg Sustained-Release Tablet
* price without discount in nearest pharmacy. Price may vary.
We offer free Gliclazide coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your discount card in most local pharmacies to get a discount on Gliclazide every time. What are you waiting for? Claim your prescription drug card now!
Gliclazide volume of distribution
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Gliclazide
Gliclazide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating beta; cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic beta; cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Gliclazide has been shown to decrease fasting plasma glucose, postprandial blood glucose and glycosolated hemoglobin (HbA1c) levels (reflective of the last 8-10 weeks of glucose control). Gliclazide is extensively metabolized by the liver; its metabolites are excreted in both urine (60-70%) and feces (10-20%).
Gliclazide mechanism of action
Gliclazide binds to the beta; cell sulfonyl urea receptor (SUR1). This binding subsequently blocks the ATP sensitive potassium channels. The binding results in closure of the channels and leads to a resulting decrease in potassium efflux leads to depolarization of the beta; cells. This opens voltage-dependent calcium channels in the beta; cell resulting in calmodulin activation, which in turn leads to exocytosis of insulin containing secretorty granules.
Dosage forms of Gliclazide
|Tablet (extended-release)||oral||60 mg|
|Tablet (extended-release)||oral||30 mg|
Act Gliclazide Mr
Actavis Pharma Company
Humans and other mammals
Indication of Gliclazide
For the treatment of NIDDM in conjunction with diet and exercise.
Toxicity of Gliclazide
LD sub50 /sub=3000 mg/kg (orally in mice). Gliclazide and its metabolites may accumulate in those with severe hepatic and/or renal dysfunction. Symptoms of hypoglycemia include: dizziness, lack of energy, drowsiness, headache and sweating.
RX24 Drugs Disclaimer: before buying a Gliclazide on prescription, consult your healthcare provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.